Eltrombopag Drugs Market Size Projected to Drive USD 5.28 Billion by 2034

The global eltrombopag drugs market is valued at USD 2.66 billion in 2025 and is projected to expand to approximately USD 5.28 billion by 2034, advancing at a CAGR of 7.94% during the forecast period.

Ottawa, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global eltrombopag drugs market size was valued at USD 2.46 billion in 2024 and is projected to reach USD 5.28 billion by 2034, expanding at a CAGR of 7.94%, according to a study by Towards Healthcare, a sister company of Precedence Research.

The growth of the market is driven by the increasing prevalence of chronic immune thrombocytopenia and severe aplastic anemia, which demand for the market fuelling the demand for the market.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5299

Key Takeaways

North America dominated the eltrombopag drugs market in 2023.
Asia Pacific is expected to grow at the fastest rate during the forecast period.
By type, the tablets segment held a significant share of the eltrombopag drugs market in 2023.
By application, the hospitals and clinics segment held the major share of the eltrombopag drugs market in 2023.

Market Overview & Potential

Thrombocytopenia, or reduced platelets in the blood, is a blood condition known as chronic immune thrombocytopenia (ITP), which is treated with eltrombopag. This medication is used after a splenectomy or surgery to remove the spleen when other medications, such as immunoglobulin or steroids, have not been effective enough. Eltrombopag is also used in conjunction with interferon therapy to treat thrombocytopenia in individuals with chronic hepatitis C.

What is the Growth Potential Responsible for The Growth of The Eltrombopag Drugs Market?

The growth of the market is driven by the increasing prevalence of chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA), which demand advanced therapy and treatment, fueling the growth of the market. Recommendations from organizations like the American Society of Hematology (ASH) and the European Hematology Association (EHA) further increase the use and demand for the market.

Other key drivers are the increased healthcare expenditure and improved diagnostics, cost effectiveness, advancemnets in treatment guidelines, which fuel the growth and expansion of the market.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What Are the Growing Trends Associated with the Eltrombopag Drugs Market?

Rising Prevalence of Thrombocytopenia:

The rising prevalence and conditions like chronic IPT and cases where eltromopag is the key treatment increase the demand and promote the growth of the market.

Eltrombopag's Efficacy:

The efficiency and results, like increasing platelet production, increase the demand and adoption of the treatment for patients with low platelet counts.

Innovation and Research:

The ongoing research and development in optimizing eltrombopag's use and the development of new and innovative formulation further boosts the growth of the market.

Precision Medicine and Personalized Healthcare:

Growing demand and adoption of targeted therapy with a personalized approach to increase the efficiency of the treatment will help in the growth of the market.

What Is the Growing Challenge in the Eltrombopag Drugs Market?

The key growth challenge that hinders the growth of the market is the high cost of research and development, which is a financial burden limiting the use and also affecting the adoption. The limited accessibility and need for specialized diagnosis and monitoring also lead to high cost, which creates barriers to access and limits and impacts the growth of the market. Eltrombopag can cause serious liver problems. Healthcare providers need to carefully monitor patients for side effects like nausea, vomiting, dark urine, and jaundice. These factors limit the growth and also hinder the expansion of the market.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Regional Analysis

How Did North America Dominate the Eltrombopag Drugs Market in 2024?

The North American eltrombopag market is substantial, with the region leading globally. This leadership is driven by the rising diagnosis of conditions such as chronic immune thrombocytopenia (ITP) and severe aplastic anemia, for which eltrombopag is a recognized treatment. Novartis reported notable sales of Promacta/Revolade (eltrombopag), indicating steady demand. The presence of generic options also boosts market activity.

Factors such as ongoing research, collaboration among industry leaders, government support, and investments in healthcare improvements contribute to North America's prominence. All stakeholders are actively working to enhance care standards and expand treatment options. The U.S. and Canada are the primary drivers of this growth. Despite breakthroughs, the number of disorders requiring eltrombopag therapy continues to rise.

What factors contributed to Asia Pacific's significant growth in the eltrombopag market in 2024?

The Asia Pacific eltrombopag market is expanding due to increased healthcare spending, greater awareness of hematological disorders, and better diagnostic methods. The rapid growth is also fueled by foreign investment and cooperation among industry players. The region’s large population provides a substantial workforce advantage. To achieve a leading global position and improve therapies, many market participants in Asia Pacific are investing in research and development. The market remains competitive, with key companies expanding their product ranges through new launches, strategic alliances, and mergers and acquisitions.

According to Volza's India Export data, India shipped out 75 Eltrombopag shipments from October 2023 to September 2024 (TTM). These exports were handled by 17 Indian exporters to 40 buyers, showing a growth rate of 29% over the previous 12 months.
Globally, India, China, and Croatia are the top three exporters of Eltrombopag. India is the global leader in Eltrombopag exports with 297 shipments, followed closely by China with 64 shipments, and Croatia in third place with 34 shipments.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Segmental Insights

By Type

Which Type Segment Dominated the Eltrombopag Drugs Market In 2024?

The tablets segment held a significant share of the eltrombopag drugs market. Oral medication is the most common method because it is easy, inexpensive, painless, and has high patient compliance, offering various dose forms. To be suitable for oral administration, a drug must be highly soluble in water, which enhances its bioavailability. Eltrombopag is used to treat thrombocytopenia, characterized by low platelet counts, in patients with chronic immune thrombocytopenia (ITP). It is prescribed after a splenectomy (spleen removal surgery) and when other treatments like steroids or immunoglobulin are ineffective.

By Application

How Did Hospitals And Clinics Segment Dominated the Eltrombopag Drugs Market In 2024?

The hospitals and clinics segment held the major share of the eltrombopag drugs market in 2023. Hospital stays are essential for treating and monitoring patients with acute myeloid leukemia, chronic liver disease, chronic immune thrombocytopenia, and other conditions. Consequently, hospitals are the main settings for TPO-RA treatment. Patients prefer hospitals because they provide comprehensive resources for interdisciplinary care. This medication is also used to treat low platelet counts caused by primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection. ITP is an autoimmune disorder where the immune system destroys platelets.

Recent Developments

In October 2024, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited received approval from China's National Medical Products Administration to market Eltrombopag Olamine tablets.
In January 2024, the National Medical Products Administration of China authorized the Group's "Eltrombopag Olamine Tablets" (trade name: Taipusheng) for sale to adults and children aged six and above, according to a statement released by the board of directors of Sino Biopharmaceutical Limited.

Browse More Insights of Towards Healthcare:

The drug supply chain market is rapidly evolving worldwide, with revenue expected to accumulate in the hundreds of millions between 2025 and 2034.

The global cancer drug manufacturing market is witnessing robust expansion, with forecasts projecting revenue growth reaching several hundred million dollars by the end of the forecast period (2025–2034).

The U.S. oncology pharmaceuticals market continues its upward momentum, with substantial revenue potential anticipated to climb into the hundreds of millions over the coming decade.

Specifically, the U.S. oncology drugs market was valued at USD 95.69 billion in 2024, expanded to USD 105.2 billion in 2025, and is projected to reach approximately USD 246.85 billion by 2034, growing at a CAGR of 9.94% from 2025 to 2034.

The global cell-based assays market stood at USD 17.29 billion in 2024 and is expected to grow to USD 18.82 billion in 2025. By 2034, it is projected to surpass USD 39.92 billion, advancing at a CAGR of 8.84%.

The radiation-induced dermatitis drug market was valued at USD 510 million in 2024, increased to USD 528.56 million in 2025, and is forecast to reach around USD 729.2 million by 2034, reflecting a CAGR of 3.64% during 2025–2034.

The biopharmaceutical contract manufacturing market reached USD 40.14 billion in 2024, grew to USD 44.61 billion in 2025, and is projected to achieve around USD 115.65 billion by 2034, expanding at a CAGR of 11.14%.

The radionuclide drug conjugates (RDC) market was valued at USD 3.24 billion in 2024, rose to USD 3.58 billion in 2025, and is forecast to hit approximately USD 8.87 billion by 2034, progressing at a CAGR of 10.54%.

The antibiotic-coated surgical implant drug market accounted for USD 1.17 billion in 2024, grew to USD 1.29 billion in 2025, and is projected to reach USD 3.05 billion by 2034, registering a CAGR of 10.05%.

The originator drug market was valued at USD 24.54 billion in 2024, increased to USD 26.37 billion in 2025, and is anticipated to grow to around USD 50.05 billion by 2034, advancing at a CAGR of 7.44%.

Eltrombopag Drugs Market Key Players

Ningbo Menovo Tiankang Pharmaceutical
Longfu Pharmaceutical
Guangdong
Shandong Jewim Pharmaceutical
Novartis
Changzhou Pharmaceutical Factory
Chia Tai Tianqing Pharmaceutical
Zhejiang Hisun Pharmaceutical
Grand Pharmaceutical
Qilu Pharmaceutical
Sichuan Kelun Pharmaceutical
Amneal Pharmaceuticals
Actavis Laboratories
Hetero
Annora Pharma
Teva Pharmaceuticals

Segments Covered in The Report

By Type

Tablets
Oral Suspension

By Application

Hospitals and Clinics
Pharmacy
Other

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5299

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.